Statera BioPharma (FRA:7CB) Total Operating Expense: €17.17 Mil (TTM As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Total Operating Expense?

Statera BioPharma FRA:7CB 20 Total Operating Expense is €17.17 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Total Operating Expense for the three months ended in Sep. 2022 was €1.31 Mil. Statera BioPharma's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 was €17.17 Mil.

Statera BioPharma Total Operating Expense Related Terms

Statera BioPharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Total Operating Expense Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Total Operating Expense
2.53 8.97 25.51

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 7.39 7.97 5.49 2.40 1.31
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €17.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €17.17 Mil mean?
Statera BioPharma (FRA:7CB) has a Total Operating Expense of €17.17 Mil as of Sep. 2022. Total operating expense is the primary recurring expense associated with central operations. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Total Operating Expense too high?
Statera BioPharma's current Total Operating Expense is €17.17 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Total Operating Expense compare to NRBO and PALI?
Statera BioPharma's Total Operating Expense of €17.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Total Operating Expense is €17.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Total Operating Expense of €17.17 Mil. The current Total Operating Expense is €17.17 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Total Operating Expense is €17.17 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price